Lee Hyuk-Joon, Kim Yoon Ho, Kim Woo Ho, Lee Kuhn Uk, Choe Kuk Jin, Kim Jin-Pok, Yang Han-Kwang
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Jpn J Clin Oncol. 2003 May;33(5):209-14. doi: 10.1093/jjco/hyg042.
Although the prognosis of early gastric cancer (EGC) is considered to be satisfactory, some patients experience disease recurrence after curative resection. This study was aimed at evaluating the recurrence rate, the recurrence patterns and the prognostic factors for recurrence of EGC as well as treatment results after recurrences.
We investigated follow-up records of 1452 EGC patients on whom curative operations were performed at Seoul National University Hospital from 1986 to 1995 with special reference to cancer recurrence.
Twenty-one patients showed recurrences with a 1.5% 5-year cumulative recurrence rate. Four cases were locoregional recurrences, two were peritoneal recurrences, nine were distant recurrences and six were mixed type recurrences. The 5-year survival rates of T1N0, T1N1, T1N2 and T1N3 were 99.3, 96.8, 72.7 and 0%, respectively (P < 0.001). Multivariate analysis revealed a significantly high correlation between positive lymph node metastasis and recurrence (P < 0.001). Median survival after recurrence of EGC was 4.3 months. Median survival after recurrence was 5.8 months after chemotherapy and 3.1 months after conservative management (P = 0.69).
Although the recurrence of EGC is very rare in general, EGC with lymph node metastasis has a higher possibility of recurring, especially with >6 positive lymph nodes. Even after curative resection of EGC, patients with EGC with >6 positive lymph nodes should be closely followed and be considered as candidates for adjuvant treatment.
尽管早期胃癌(EGC)的预后被认为是令人满意的,但一些患者在根治性切除术后会出现疾病复发。本研究旨在评估EGC的复发率、复发模式和复发的预后因素以及复发后的治疗结果。
我们调查了1986年至1995年在首尔国立大学医院接受根治性手术的1452例EGC患者的随访记录,特别关注癌症复发情况。
21例患者出现复发,5年累积复发率为1.5%。4例为局部复发,2例为腹膜复发,9例为远处复发,6例为混合型复发。T1N0、T1N1、T1N2和T1N3的5年生存率分别为99.3%、96.8%、72.7%和0%(P<0.001)。多变量分析显示阳性淋巴结转移与复发之间存在显著高度相关性(P<0.001)。EGC复发后的中位生存期为4.3个月。复发后化疗后的中位生存期为5.8个月,保守治疗后的中位生存期为3.1个月(P=0.69)。
尽管EGC总体复发非常罕见,但伴有淋巴结转移的EGC复发可能性更高,尤其是阳性淋巴结>6个时。即使EGC根治性切除术后,阳性淋巴结>6个的EGC患者也应密切随访,并被视为辅助治疗的候选者。